中国人群力证:长效EPO显著提高肾性贫血达标率 肾性贫血是慢性肾脏病(CKD)重要的并发症,也是常见的合并症,影响着CKD患者的生活质量,且增加肾脏疾病进展、终末期肾脏病(ESRD)、心血管(CV)事件及死亡的风险1。尽管肾性贫血治疗药物不断涌现,但血红蛋白(Hb)达...
3.高峰,等. 促红细胞生成素在贫血治疗中的应用进展及市场简析[J]. 中国新药杂志,2020,29(10):1110-1117. 4.Cody JD, Hodson EM. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in p...
3.高峰,等. 促红细胞生成素在贫血治疗中的应用进展及市场简析[J]. 中国新药杂志,2020,29(10):1110-1117. 4.Cody JD, Hodson EM. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database Syst Rev. 2...
saline Chronic kidney disease DPO s.c. 0.4 μg/kg/wk into 5/6 remnant kidney rats after renal mass reduction ↑microvascular density, ↑endothelial proliferation, preserved renal function (↓SCr), ↓scarring, ↑VEGF expression Hemorrhagic shock and endotoxic shock EPO 300 U/kg i.v. before ...
EPO Therapy During Acute Kidney Disease: To Use or Not to Use, That Is the Questiondoi:10.1053/j.ajkd.2005.08.022EdwardKrausandHamidRabbSDOSAmerican Journal of Kidney Diseases
4.Hayashi T, Joki N, Tanaka Y, et al. Anaemia and early phase cardiovascular events on haemodialysis[J]. Nephrology (Carlton), 2015, 20 Suppl 4: 16. 5.KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease.Kidney International Supplements (2012) 2, 279; doi:10.1038/kisup...
研究背景和目的 血管钙化的现象在慢性肾脏病(chronic kidney disease,CKD)患者中十分常见,并且是导致CKD患者心血管疾病高发的重要原因之一.促红细胞生成素(Erythropoietin,EPO)被广泛应用于治疗肾性贫血,但临床研究发现EPO的剂量与CKD患者心血管疾病的发病率及死亡率密切相关.近年来的基础研究发现,EPO可以促进成骨细胞及...
Erythropoietin Activates Mitochondrial Biogenesis and Couples Red Cell Mass to Mitochondrial Mass in the Heart Erythropoietin (EPO) is often administered to cardiac patients with anemia, particularly from chronic kidney disease, and stimulation of erythropoiesis may... MS Carraway,HB Suliman,WS Jones,.....
An overview of anemia management trends at the regional and country specific levels in the Gulf Cooperation Council countries. Saudi J Kidney Dis Transpl. 2016 Nov;27(6 Suppl 1):51-61.7.KDIGO Clinical Practice Guideline Working Group. Kidney Int Suppl, 2012, 2: 279⁃3358.Yamamoto, H., Ni...
目前随着现代基因技术的发展,r-HuEPO已成功广泛应用于临床慢性肾脏病(chronic kidney disease,CKD)患者,有研究显示,慢性肾脏病患者对EPO反应性的降低是疾病进展的主要原因,体内炎性反应因子也能不同程度地降低机体对EPO的反应性[3],所以说EPO可显著延缓慢性肾脏病的进展[4-6]。此外,EPO还适用于癌症、化疗或者外科...